Disease

Thyroid tumor

Clinical development underway

Also known as neoplasm of the thyroid, neoplasm of the thyroid gland, neoplasm of thyroid, neoplasm of thyroid gland+15 more

neoplasm of the thyroid, neoplasm of the thyroid gland, neoplasm of thyroid, neoplasm of thyroid gland, thyroid gland neoplasm, thyroid gland neoplasm (disease), thyroid gland tumor, thyroid gland tumour, thyroid neoplasm, thyroid neoplasms, tumor of the thyroid, tumor of the thyroid gland, tumor of thyroid, tumor of thyroid gland, tumour of the thyroid, tumour of the thyroid gland, tumour of thyroid, tumour of thyroid gland, THYROID.

Clinical trials

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Teprotumumabapproved

Approval — Treatment of moderate to severe thyroid eye disease (TED). (2025)

Selpercatinibapproved

Approval — Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusi… (2021)

Cabozantinibapproved

Accelerated approval — Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell… (2016)

Trametinibapproved

Approval — Melanoma Trametinib as monotherapy or in combination with dabrafenib is indicat… (2014)

Dabrafenibapproved

Approval — Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the… (2013)

Vandetanibapproved

Approval — Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid c… (2012)

Sorafenibapproved

Approval — Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcino… (2006)

Clinical trials

1 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Recently completed

Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy

N/A · Completed · Chosun University Hospital

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals

2025emaApproval — Teprotumumab· Treatment of moderate to severe thyroid eye disease (TED). source ↗

2021emaApproval — Selpercatinib· Retsevmo as monotherapy is indicated for the treatment of adults with: advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. For biomarker-based patient selection, see section 4.2.  Retsevmo as monotherapy is indicated for the treatment of adults and paediatric patients 2  years of age and older with: advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) . For biomarker-based patient selection, see section 4.2. advanced RET mutant medullary thyroid cancer (MTC) . For biomarker-based patient selection, see section 4.2. advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections  4.4 and 5.1). For biomarker-based patient selection, see section 4.2. source ↗

2016emaAccelerated approval — Cabozantinib· Renal Cell Carcinoma (RCC) Cabometyx is indicated as monotherapy for advanced renal cell carcinoma as first-line treatment of adult patients with intermediate or poor risk, in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. Hepatocellular carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.Differentiated thyroid carcinoma (DTC)Cabometyx is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy.Neuroendocrine Tumours (NET)Cabometyx is indicated for the treatment of adult patients with unresectable or metastatic, well differentiated extra-pancreatic (epNET) and pancreatic (pNET) neuroendocrine tumours who have progressed following at least one prior systemic therapy other than somatostatin analogues. source ↗

2014emaApproval — Trametinib· Melanoma Trametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adults and adolescents aged 12 years and older with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1). Adjuvant treatment of melanoma Trametinib in combination with dabrafenib is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Trametinib in combination with dabrafenib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation. Differentiated thyroid cancer (DTC) Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2). source ↗

2014emaApproval — Cabozantinib· Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. source ↗

2013emaApproval — Dabrafenib· Melanoma Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adults and adolescents aged 12 years and older with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1). Adjuvant treatment of melanoma Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage III melanoma with a BRAF V600 mutation, following complete resection. Non-small cell lung cancer (NSCLC) Dabrafenib in combination with trametinib is indicated for the treatment of adults with advanced non-small cell lung cancer with a BRAF V600 mutation. Differentiated thyroid cancer (DTC) Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with locally advanced or metastatic differentiated thyroid cancer with a BRAF V600E mutation, refractory to or not eligible for radioactive iodine (RAI) who have progressed during or after prior systemic therapy (for biomarker-based patient selection, see section 4.2). source ↗

2012emaApproval — Vandetanib· Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease. Caprelsa is indicated in adults, children and adolescents aged 5 years and older. For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision. source ↗

2006emaApproval — Sorafenib· Hepatocellular carcinoma Nexavar is indicated for the treatment of hepatocellular carcinoma. Renal cell carcinoma Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. Differentiated thyroid carcinoma Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

CCDC60.46 NCOA40.39 EPHB30.37 NCOR10.37 CBFA2T30.37 EPHA10.37 EPHA40.37 NAB20.37 ZNF6760.11 DHX320.11 ZNF7300.09 ZNF2570.04

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Coiled-coil domain-containing protein 6via CCDC60.46

Reference

Authoritative identity, definition & identifiers.

Synonyms

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Related entities are derived from literature co-mention (studied together) — associative, not causal.